Angiochem Reports Positive Clinical Data with ANG1005 in Breast Cancer Patients with Leptomeningeal Carcinomatosis
Angiochem, a biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) announced positive clinical results with ANG1005, a novel paclitaxel-peptide drug conjugate, in breast cancer patients with leptomeningeal carcinomatosis (LC), a metastatic cancer that spreads rapidly to the membranes of the brain and spinal cord. Interim data from this ongoing Phase 2 study were presented at the 20th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) at San Antonio, Texas. Based on these results, Angiochem is developing a multi-study Phase 3 clinical program to evaluate ANG1005 in breast cancer patients with or without LC.
In a poster titled "ANG1005, a Novel Brain-penetrant Peptide-taxane Conjugate, for the Treatment of CNS Metastases from Breast Cancer," Angiochem researchers and collaborators at Northwestern University and other clinical centers reported interim Phase 2 study results demonstrating that breast cancer patients with brain metastases treated with ANG1005, including a subset of patients with LC, achieved encouraging responses. Of the 21 heavily pre-treated patients with LC, 5 patients (24%) achieved a partial response (PR) and 11 patients (52%) had stable disease (SD) as best intracranial response. The Kaplan-Meier estimates of survival in patients with LC treated with ANG1005 predict a median survival (95% CI) of 38.4 weeks as compared to 4-6 weeks if left untreated or 12-24 weeks with conventional chemotherapy. In addition, ANG1005 demonstrated intracranial and extracranial antitumor activity in patients with various other subtypes of breast cancer including patients previously treated with paclitaxel. ANG1005 was shown to be generally safe and well-tolerated, and demonstrated an adverse event profile consistent with conventional taxane therapy at both dose levels studied (550mg/m2 and 600mg/m2).
"With more than 20,000 patients diagnosed in the United States each year, leptomeningeal carcinomatosis remains one of the most challenging and fatal forms of brain metastases to effectively treat," said Priya U. Kumthekar MD, of the Northwestern Brain Tumor Institute, Northwestern University. "These promising results for ANG1005 warrant further evaluation of the drug in this patient population."
About leptomeningeal carcinomatosis (LC)
Leptomeningeal carcinomatosis (LC) is a form of metastatic cancer that has spread to the membranes of the brain and spinal cord. There are 20-30,000 patients diagnosed with LC in the United States each year. If left untreated, median survival is 4-6 weeks; if treated, historical median survival is 3-6 months.
ANG1005 is a novel paclitaxel-peptide drug conjugate that represents the first oncology product to leverage the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 has been studied in over 300 patients in six clinical studies. A multi-study Phase 3 clinical program is in development for breast cancer leptomeningeal carcinomatosis with or without brain metastasis, and separately, brain metastasis without LC.
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.
Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.
The Yates Network
Gina Nugent, 617-460-3579
Business Development Contact:
Michael Garrett, 919-597-9297